- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00867464
Utvidet oppfølging av unge kvinner i Costa Rica som mottok vaksine for humant papillomavirus type 16 og 18 og uvaksinerte kontroller
Utvidet oppfølging av unge kvinner i Costa Rica som mottok vaksinasjon mot humant papillomavirus type 16 og 18 og uvaksinerte kontroller
This research trial studies extended follow up of young women in Costa Rica who received vaccine for human papillomavirus types 16 and 18 and unvaccinated controls. Collecting information from young women in Costa Rica who have received vaccine for human papillomavirus types 16 and 18 and a new group of unvaccinated controls enrolled for the follow-up period, may help doctors learn more about the risks and benefits of prophylactic human papillomavirus vaccine.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
PRIMARY OBJECTIVES:
I. To evaluate the 10-year global impact of human papillomavirus (HPV)-16/18 vaccination of young adult women.
II. To evaluate determinants of the immune response to HPV and the vaccine, and markers of long-term protection.
III. To evaluate the natural history of HPV and cervical disease in vaccinated and unvaccinated populations.
OUTLINE:
Participants undergo long term follow-up comprising risk factor questionnaire, pelvic examination for all sexually experienced women, and specimen collection at years 6, 8, and 10.
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiesteder
-
-
Guanacaste Province
-
Liberia, Guanacaste Province, Costa Rica, 50101
- Agencia Costarricense de Investigaciones Biomédicas (ACIB)
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Young women in Costa Rica who received vaccination against human papillomavirus types 16 and 18 and unvaccinated controls.
Beskrivelse
Inclusion Criteria:
- Women who participated in the Costa Rica Vaccine Trial (CVT) and lived in the Guanacaste province and a few areas of Puntarenas closest to Guanacaste will be eligible for the long-term follow up LTFU study
- Women who received the HPV-16/18 vaccine at the start of CVT will be invited for up to 6 years of additional follow-up, and women who were originally in the control arm of CVT and were offered the HPV-16/18 vaccine at crossover will be invited for an additional 2 years of follow-up
- A subset of the control arm women who are in the crossover immunogenicity subcohort will be followed the full 6 years
- Some women who received HPV vaccination and were not invited into the LTFU protocol (stopped attending their screening visits during CVT, discontinued their study participation during CVT or lived outside the study area) will be invited to participate in the LTFU protocol, particularly those who received an incomplete vaccination schedule
- UNVACCINATED CONTROL GROUP:
- Born in or between July 1978 and November 1987
- Residents of Guanacaste Province and a few areas of Puntarenas closest to Guanacaste at some point during 2005
- Able to speak/understand Spanish
- Apparently mentally competent
- Written informed consent obtained prior to enrollment
Exclusion Criteria:
- History of cervical cancer
- History of hysterectomy
- Any important medical condition or other criteria that the investigator considers that precludes enrollment
- Vaccination with Gardasil or Cervarix will be an exclusionary criterion, but few women are expected to have received these vaccines at the time of enrollment; use of these vaccines after enrollment is not a criterion for study interruption but we plan to collect information on vaccination history so that the few women who report having been vaccinated with one of the HPV vaccines after enrollment can be evaluated separately at analysis
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: CASE_CONTROL
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Observational (long term follow-up)
Participants undergo long term follow-up comprising risk factor questionnaire, pelvic examination for all sexually experienced women, and specimen collection at years 6, 8, and 10. |
Correlative studies Ancillary studies Correlative studies
Andre navn:
Undergo extended follow-up
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Cumulative rate of cervical intraepithelial neoplasia 3 (CIN3)
Tidsramme: At 10 years
|
Both absolute rate differences and percent reduction in rates will be evaluated. |
At 10 years
|
|
Level of immune response markers as prediction of long-term success of HPV vaccine
Tidsramme: Up to 10 years
|
For efficiency, a nested case-control approach is envisioned to evaluate this question. We propose to compare women who become infected against a subset of those who do not (non-failures) with respect to immune response markers of interest. |
Up to 10 years
|
|
Increase in the rate of cervical lesions associated with other carcinogenic HPV types that the vaccine does not protect against from prevention of HPV-16/18 associated cervical lesions through vaccination
Tidsramme: Up to 10 years
|
The 10-year cumulative rate of incident CIN2+ associated with HPV types other than HPV-16/18 and closely related HPV types in the alpha-7/9 species for which evidence of vaccine cross-protection is demonstrated will be compared between vaccinated and unvaccinated women. |
Up to 10 years
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Aimee Kreimer, National Cancer Institute (NCI)
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Shing JZ, Hu S, Herrero R, Hildesheim A, Porras C, Sampson JN, Schussler J, Schiller JT, Lowy DR, Sierra MS, Carvajal L, Kreimer AR; Costa Rica HPV Vaccine Trial Group. Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial. Lancet Oncol. 2022 Jul;23(7):940-949. doi: 10.1016/S1470-2045(22)00291-1. Epub 2022 Jun 13.
- Porras C, Tsang SH, Herrero R, Guillen D, Darragh TM, Stoler MH, Hildesheim A, Wagner S, Boland J, Lowy DR, Schiller JT, Schiffman M, Schussler J, Gail MH, Quint W, Ocampo R, Morales J, Rodriguez AC, Hu S, Sampson JN, Kreimer AR; Costa Rica Vaccine Trial Group. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial. Lancet Oncol. 2020 Dec;21(12):1643-1652. doi: 10.1016/S1470-2045(20)30524-6.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Antatt)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Kjønnssykdommer
- Munnsykdommer
- Stomatognatiske sykdommer
- Patologiske prosesser
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Sykdomsattributter
- Tarmsykdommer
- Infeksjoner
- Virussykdommer
- Gastrointestinale neoplasmer
- Neoplasmer i fordøyelsessystemet
- Sykdommer i fordøyelsessystemet
- Gastrointestinale sykdommer
- Kolorektale neoplasmer
- Intestinale neoplasmer
- Rektale sykdommer
- Livmorsykdommer
- Kjønnssykdommer, kvinner
- Neoplasmer i hode og nakke
- Smittsomme sykdommer
- Seksuelt overførbare sykdommer, virale
- Seksuelt overførbare sykdommer
- DNA-virusinfeksjoner
- Genitale neoplasmer, kvinnelige
- Livmor livmorhalssykdommer
- Uterine neoplasmer
- Tumorvirusinfeksjoner
- Anus sykdommer
- Rektale neoplasmer
- Patologiske tilstander, tegn og symptomer
- Uterine cervikale neoplasmer
- Papillomavirusinfeksjoner
- Neoplasmer i munnen
- Neoplasmer i anus
Andre studie-ID-numre
- NCI-2016-00231
- NCI-2016-00231 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
- 999909106
- 09-C-N106 (Annen identifikator: National Cancer Institute)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .